Your Health, We Care
In the pursuit of health and recovery, rational use of drugs is a crucial part. Patients should be fully aware of the information about the drug, including but not limited to efficacy, dosage, and contraindications, before using any drug. Be sure to follow the doctor's guidance and do not increase or decrease the dose or change the drug at will, so as not to affect the efficacy or cause adverse reactions; Be aware of drug-drug interactions and avoid self-medication.
In 2022, Alpelisib received accelerated FDA approval for patients on the PIK3CA-associated overgrowth disease spectrum, particularly those adults and children over 2 years of age w···【more】
Article source：Captain MedicineRelease date：2024-08-27Recommended：313
As the first oral small molecule drug for HR/HER2- and PIK3CA-mutated advanced breast cancer, Alpelisib effectively prolongs the progression-free survival of patients by inhibiting···【more】
Article source：Captain MedicineRelease date：2024-08-27Recommended：274
In 2022, Alpelisib received accelerated FDA approval for the treatment of adults and children over 2 years of age on the PIK3CA-associated overgrowth disease spectrum, an expanded ···【more】
Article source：Captain MedicineRelease date：2024-08-27Recommended：263
Balversa is currently a new star in the field of anti-cancer, which is used orally to treat FGFR mutant tumors such as urothelial carcinoma, has extraordinary effects in the field ···【more】
Article source：Captain MedicineRelease date：2024-08-27Recommended：283
Alpelisib was approved by the FDA in 2019 as a PIK3CA kinase inhibitor in combination with fulvestrant, providing a new treatment option for patients with advanced breast cancer wi···【more】
Article source：Captain MedicineRelease date：2024-08-27Recommended：275
Balversa is a new oral anti-cancer star on the market, showing excellent tumor suppression effects against FGFR mutant tumors such as urothelial carcinoma, but it has not yet been ···【more】
Article source：Captain MedicineRelease date：2024-08-27Recommended：256
Alpelisib was approved by the FDA in May 2019 for use in combination with fulvestrant to inhibit tumor progression in postmenopausal women and men with advanced breast cancer with ···【more】
Article source：Captain MedicineRelease date：2024-08-27Recommended：311
As a PIK3CA kinase inhibitor, Alpelisib plays an important role in the relationship between the activation of the PI3K pathway and tumor drug resistance, especially in patients wit···【more】
Article source：Captain MedicineRelease date：2024-08-27Recommended：306
Balversais an oral anti-cancer star targeting FGFR mutations, which has a significant inhibitory effect on tumors such as urothelial carcinoma, but it has not yet landed in the dom···【more】
Article source：Captain MedicineRelease date：2024-08-27Recommended：344
Balversa is an oral anticancer drug that specializes in FGFR mutant tumors, such as urothelial carcinoma, and effectively inhibits tumor proliferation, but has not yet been introdu···【more】
Article source：Captain MedicineRelease date：2024-08-27Recommended：326
Balversa is an oral anticancer drug used for the treatment of locally advanced or metastatic urothelial carcinoma, inhibiting FGFR activity to stop tumor growth, but it is not curr···【more】
Article source：Captain MedicineRelease date：2024-08-27Recommended：292
Accurately understanding the dosage of Balversa is the key to achieving the best treatment results. Below, let's discuss the dosage of Balversa in detail.What is the dosage of ···【more】
Article source：Captain MedicineRelease date：2024-08-27Recommended：243
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended：2272025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended：4542024-09-07
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended：2342025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended：2472025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended：2272025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended：2582025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended：2372025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended：2182025-27-11
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp:
